©The Author(s) 2019.
World J Hepatol. May 27, 2019; 11(5): 450-463
Published online May 27, 2019. doi: 10.4254/wjh.v11.i5.450
Published online May 27, 2019. doi: 10.4254/wjh.v11.i5.450
Table 1 Medical management of pruritus in children
| Medicine | Dose | Mechanism of action |
| Cholestyramine | Initial dose: 2 g BID | Ion exchange resin which acts as BA binder in the intestine |
| (max dose 24 g/d) | Decreased ileal BA absorption, Increased BA excretion (in feces) | |
| Naltrexone | Initial dose: 0.25-5 mg/kg per day | Opioid antagonist |
| (max dose 50 mg/d) | Block the permissive activity on pruritus neuronal signaling | |
| Rifampicin | Initial dose: 5 mg/kg | PXR agonist |
| Induces CYP3A4 | ||
| (max dose 20 mg/kg per day) | Increases metabolism and renal excretion of pruritogenic substances | |
| Antibacterial effect may modify intestinal metabolism of pruritogenic substances | ||
| Sertraline | Initial dose: 1 mg/kg per day | Serotonin reuptake inhibitor |
| (max dose: 4 mg/kg per day) | Proposed mechanism includes increase in central serotonergic tone, which regulates pruritus | |
| Ursodeoxycholic acid | 600 mg/m2 per day | Tertiary BA |
| Increases bile secretion | ||
| Reduces ileal absorption of hydrophilic BAs |
- Citation: Henkel SA, Squires JH, Ayers M, Ganoza A, Mckiernan P, Squires JE. Expanding etiology of progressive familial intrahepatic cholestasis. World J Hepatol 2019; 11(5): 450-463
- URL: https://www.wjgnet.com/1948-5182/full/v11/i5/450.htm
- DOI: https://dx.doi.org/10.4254/wjh.v11.i5.450